Optimization of LpxC inhibitor lead compounds focusing on efficacy and formulation for high dose intravenous administration.
暂无分享，去创建一个
D. Ritz | R. Lange | S. Diethelm | H. Locher | F. Masse | P. Seiler | C. Gnerre | Swen Seeland | C. Schmitt | G. Rueedi | P. Panchaud | J. Surivet | M. Enderlin-Paput | Jean-Christophe Gauvin | A. Mirre | Anne-Catherine Blumstein | L. Jacob | G. Mathieu | C. Herrmann